Mesoblast Limited (ASX:MSB) have entered into a strategic alliance with Cephalon (CEPH) to develop and commercialize novel adult Mesenchymal Precursor Stem Cell (MPC) therapeutics for degenerative ...

Cephalon (NASDAQ:CEPH): Q3 EPS of $2.27 beats by $0.48. Revenue of $717M (+30.5%) vs. $720M. (PR) Recommended For You ...